* ENDRA Life Sciences Inc reported a quarterly adjusted loss of $9.54 per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-700.00. The lone analyst forecast for the quarter was for a loss of $62.30 per share.
* Reported revenue was zero; analysts expected zero.
* ENDRA Life Sciences Inc's reported EPS for the quarter was a loss of $9.54.
* The company reported a quarterly loss of $2.35 million.
* ENDRA Life Sciences Inc shares had fallen by 24.8% this quarter and lost 99.9% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by about 11% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for ENDRA Life Sciences Inc is 350.00 This summary was machine generated from LSEG data November 15 at 03:53 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jan. 1 0001 -62.30 -9.54 Beat
Jun. 30 2024 -1.22 hundred -1.40 hundred Missed
Mar. 31 2024 -4.55 hundred
Dec. 31 2023 -87.50
Comments